Replies to post #242777 on Avid Bioservices Inc (CDMO)

[biopharm]

Could have the late Dr. Andrew Parsa also been on the fast track to quickly learning re: PS Targeting ?

This becomes a little shocking. Now, Dr. Wolchok has been working with platforms from the late (both young..) Dr. Philip Thorpe / Dr. Andrew Parsa.

The puzzle pieces just seem to continue to expand and I get the feeling they will all expand into the black hole, though PS Targeting will survive and help billions of people.

For now, I bet there are some phase II or III trials going on that actually target flipped PS... possible and what happens then if so? They must license out a deal with Peregrine I'd say... One such trial is this below, the one that the late Dr. Andre Parsa was the PI and the largest trial coming out of the NCI. Looks like it was a combination trial with Avastin as well....

Here is a thought to all the Phase II/III's out there that may not be even aware of their drugs MOA. Since we are now learning much more about immunotherapy, wouldn't it be easy enough to test out another drugs MOA and verify if it may be stepping on that of Peregrines and PS Targeting ?

All I know is Prophage+Avastin doubled survival over all historic norms...

pgs 27/28 ( ..only with low PD-L1 expression..)
http://www.jefferies.com/CMSFiles/Jefferies.com/files/Agenus.pdf

... something very, eerily similar to what Docetaxel+Bavituximab has accomplished in the phase IIb NSCLC and the question should be does Prophage MOA act step on Peregrines PS Targeting rights.

Time will tell...

Prophage Series G-200 is in the largest vaccine trial ever funded by the NCI in brain tumors and the largest cancer vaccine study ever conducted in combination with Avastin®.

www.agenusbio.com/science/prophage.php

[biopharm]

Could have the late Dr. Andrew Parsa also been on the fast track to quickly learning re: PS Targeting ?

This becomes a little shocking. Now, Dr. Wolchok has been working with platforms from the late (both young..) Dr. Philip Thorpe / Dr. Andrew Parsa.

Very interesting reading back on Agenus with Dr Andrew Parsa......especially in how OX40 was also on Bristol Myers Squibb mind with Dr Peter Brams (ex Medarex and big BMS )

https://patents.justia.com/inventor/peter-brams

https://www.linkedin.com/in/peter-brams-094b3a1

Remember....BMS all of a sudden announced that Medarex buyout just days after Peregrine / Medarex collaboration

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=99745193

....now seeing carefully all the Pfizer and Bristol Myers Squibb patents out of Dr Peter Brams I wonder how much PS Targeting Dr Brams had seen and brought that new knowledge possibly onto many future patents (I still say some may have found out things via PS Targeting and realized what needed to be targeted ..) and now with all that Pfizer / BMS patents....we must think back to ex-Pfizer Satish Chandran and there are much...much too many coincidences all over the place especially seeing how Satish totally tries to leave out Center of Excellence at NDSU from his bio
https://www.linkedin.com/in/satishchandransomahlution

An ex-Pfizer scientist named Satish Chandran with a history of allegedly falsifying clinical trial fraud...

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=103692048